AMPLIFICATION OF c-erbB-2 ONCOGENE IN HUMAN ADENOCARCINOMAS IN VIVO
References (19)
- et al.
The erbB gene of avian erythroblastosis virus is a member of the src gene family
Cell
(1983) Detection of specific sequences among DNA fragments separated by gel electrophoresis
J Molec Biol
(1975)- et al.
A new avain erythroblastosis virus, AEV-H, carried erbB gene responsible for the induction of both erythroblastosis and sarcomas
Cell
(1983) - et al.
Close similarity of epidermoid growth factor receptor and v-erb-B oncogene protein sequences
Nature
(1984) - et al.
Human epidermoid growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells
Nature
(1984) - et al.
The amount of EGF receptor is elevated on squamous cell carcinomas
Cancer Cells
(1984) - T. Yamamoto, N. Kamata, H. Kawano, et al., High incidence of amplification of the epidermoid growth factor receptor...
- et al.
Expression of epidermoid growth factor receptors in human brain tumors
Cancer Res
(1984) - et al.
Amplification and enhanced expression of the epidermoid growth factor receptor gene in A431 human carcinoma cells
Science
(1984)
Cited by (357)
Pan-HER-targeted approach for cancer therapy: Mechanisms, recent advances and clinical prospect
2018, Cancer LettersCitation Excerpt :The overexpression or amplification of HER2 has been observed in up to 30% of breast cancer patients and the HER2-positive subtype is significantly correlated with worse prognosis than HER2-negative breast cancer [20]. Numerous studies were performed to unveil the association between HER2 expression and survival outcome of other cancer types [21–23]. Moreover, many HER2-targeted drugs such as trastuzumab, have been developed or under clinical trials for cancer therapies, which we will describe more below.
Breast biomarker immunocytochemistry
2018, The Breast: Comprehensive Management of Benign and Malignant DiseasesErythro-austrobailignan-6 down-regulates HER2/EGFR/integrinβ3 expression via p38 activation in breast cancer
2017, PhytomedicineCitation Excerpt :It is a member of the HER (or ErbB) growth factor receptor family. Amplification or overexpression of this oncogene is important in the development and progression of certain aggressive types of breast cancer occurring in 20–30% of breast cancer patients, classified as the HER2-positive subtype, with poor clinical outcomes (Boone et al., 2009; Fukushige et al., 1986; Harris et al., 2007; King et al., 1985; Semba et al., 1985; Slamon et al., 1987; Yokota et al., 1986). The HER2 expression can lead to impaired DNA repair, angiogenesis and metastasis (Boone et al., 2009; Kumar and Yarmand-Bagheri, 2001; Palmieri et al., 2007).
A Comprehensive Review on Targeted Cancer Therapy: New Face of Treatment Approach
2023, Current Pharmaceutical Design